On February 1, 2023, Avectas announced the appointment of Dr Ann Brady as Chief Business Officer (CBO), after the successful launch of the Solupore® Platform to manufacture Next-Generation Gene-Modified Cell Therapies with Superior Cell Health and Functionality.

Dr Brady has 30 years of experience in the bio-pharma and drug-delivery industries through global leadership roles in corporate strategy, business development, alliance management, and commercial operations in both developed and emerging markets. Ann most recently served as President, Theravance Biopharma Ireland and previously held senior executive roles at Shire, plc and élan Corporation, plc. She holds a PhD in Chemistry from Trinity College, Dublin and is Chartered Director and member of the Institute of Directors.

“Ann joins the Avectas executive team as CBO at a very exciting time, as we build on the successful launch of our Solupore® platform at Advanced Therapy Week in Miami in January. We currently have several disclosed and undisclosed therapeutic and life sciences companies utilizing the technology under an early access program and we are now expanding our commercialization efforts post-launch. Ann has an impressive track record, over decades, of successfully commercializing drug delivery technology and therapeutic products, and will be instrumental in accelerating our growth.”

^{Michael Maguire, PhD, CEO of Avectas}

“I have closely followed the development of the Solupore® platform over several years and am impressed by the extensive data package generated by the team and its partners. I believe the excellent cell health and functionality post- Solupore® engineering will result in improved next-generation cell therapy products. I look forward to working with the team and leading Avectas on its journey of commercialization.”

^{Dr Ann Brady, CBO of Avectas}